Vecura
PricingSolutions
Resources
Contact us
Vecura

Product

  • Solutions
  • Pricing

Company

  • Contact us

Resources

  • Updates
  • News
  • Insights
  • Use Cases
  • Community

Legal

  • Privacy Policy
  • Terms of Service
  • Trust Center

© 2026 NYB AI. All rights reserved.

All systems operational
Vecura
PricingSolutions
Resources
Contact us

Insights

Perspectives from the Vecura team.

Research analysis, industry perspectives, and deep dives on AI for life science discovery.

Featured

From Prediction to Decision: Choosing Graph-Based AI Models for Drug-Target Interaction Research

How an output-driven perspective can help researchers select graph-based AI models for drug-target interaction research, with a closer look at DTIGN and LigoSPACE.

Jul 22, 2026Read featured story

Insights

Making Water Visible: How Generative AI Can Support Protein Structure Research

SuperWater, a generative AI framework developed to predict water molecule positions around biomolecular complexes, offers a new approach to this longstanding computational challenge.

DR. Yunchao (Lance) Liu·Jul 14, 2026

Insights

Vecura Biotech Insiders #02: De novo Antibody Design Pipelines on Vecura

In this second edition of Vecura Biotech Insiders, we highlight a workflow shared with the Vecura team by Tony 阮进成 during the support process.

All content

Insights

Vecura Biotech Insiders #03: Building a Humanized Tyrosinase Model for Structure-Based Docking

In this Vecura Biotech Insiders feature, we explore a user-shared workflow for building a copper-tagged human tyrosinase model from AlphaFold, benchmarking it against mushroom tyrosinase, and preparing it for structure-based docking.

Jul 30, 2026

Insights

Building the Active Sweet Receptor from a Cloud of Density

A walkthrough of how to build an atomic model from a cryo-EM density map

Jul 24, 2026
Previous12Next
Vecura

Product

  • Solutions
  • Pricing

Company

  • Contact us

Resources

  • Updates
  • News
  • Insights
  • Use Cases
  • Community

Legal

  • Privacy Policy
  • Terms of Service
  • Trust Center

© 2026 NYB AI. All rights reserved.

All systems operational
Jul 24, 2026

Insights

Using Boltz-2.1 for Structure Confidence Screening in a De Novo Protein Design Workflow

How the Vecura platform runs Boltz-2.1 through the API as the structure-validation engine inside a multi-model design pipeline, folding nine designed sequences with ten sampled models each and turning per-structure confidence into a triage signal for what to carry forward.

Jul 16, 2026

Insights

De Novo Design of Sartan-Like AT1R Binders for Companion-Animal Kidney Health

A Vecura workflow, chaining generative small-molecule design, structure-based docking, ADMET prediction and toxicophore-constrained redesign against the angiotensin II type 1 receptor. What the platform surfaced was not a drug candidate but something more useful, a quantified account of the potency-safety tradeoff that governs this chemotype.

Jul 15, 2026

Insights

Vecura Biotech Insiders #01: From Docking to Molecular Dynamics

A community workflow example using AutoDock Vina and GROMACS on Vecura

Jul 10, 2026

Insights

How to Slow down Amyotrophic Lateral Sclerosis - An In-Silico Approach to SOD1 Stabilization

A proposed computational pipeline for identifying small-molecule binders at the SOD1 dimer interface

Jul 3, 2026

Insights

Designing a Peptide to Hit LRRK2: A De Novo Generative Pipeline Against the ATP Pocket

A walkthrough of how modern protein design models behave when pointed at a hard, conserved kinase pocket, and what the output does and does not tell us.

Jul 3, 2026
Understanding AlphaFold: Revolutionizing Protein Folding

Insights

Understanding AlphaFold: Revolutionizing Protein Folding

AlphaFold, developed by DeepMind, is an AI system that predicts protein structures from amino acid sequences with high accuracy using deep learning, significantly advancing protein folding research. Its impact spans drug discovery, disease research, and synthetic biology, and its open-access nature has fostered global scientific collaboration—making it a landmark example of AI's potential to tackle complex biological challenges.

Jun 30, 2026

Insights

Can AI Replace 45 Hours of Manual Pose Inspection? A Covalent Docking Comparison

Covalent inhibitors occupy a unique space in drug discovery. By forming irreversible interactions with target residues, they can achieve sustained target engagement and prolonged pharmacological activity beyond what is often possible with non-covalent ligands. However, optimizing covalent scaffolds presents a distinct challenge: favorable binding affinity alone is insufficient. Productive activity depends on precise geometric alignment between the reactive warhead and the target nucleophile.

Jun 16, 2026